- With the addition of $220
million in sales, over 300 employees and therapeutic
coverage in Neurology, Oncology, Immunology, Gastroenterology,
Rare Diseases and Specialty, acquisition extends & transforms
Swixx BioPharma's footprint
- The acquisition is immediately accretive and creates a
compelling, single-stop, multi-continent partner for biopharma
companies
- The acquisition builds on Swixx BioPharma's rapid rate of
organic growth; the company has been recognized as one of
Europe's fastest growing companies
in 2024
BAAR, Switzerland, May 22, 2024
/PRNewswire/ -- Swixx BioPharma AG, a global commercial
platform dedicated to unlocking access to innovative medicines
worldwide, announces today its strategic expansion into
Latin America with the signature
of an agreement to acquire 100% of the equity of Pharma Consulting
Group S.A. the holding company of Laboratorios Biopas SA. With
operational headquarters in Bogota, Colombia, Biopas is one of
Latin America's leading
independent marketing and distribution companies for international
biopharmaceutical firms. Biopas has a presence in 20 countries,
including Latam's "Top 5" markets of Argentina, Brazil, Chile, Colombia & Mexico. Closing of the transaction is expected
after relevant regulatory approvals, anticipated in
June-July 2024.
This acquisition follows on the entry of Swixx BioPharma into
the Middle East region in
September 2023 and marks another
important step towards fulfilling Swixx's mission to become the
preferred partner for biopharma companies seeking indirect routes
to launch their medicines. Through Biopas' comprehensive Latam
continental coverage, Swixx will now be able to provide a
compelling offering covering Central and Eastern Europe, CIS/Eurasia, MENA and now
Latin America.
Biopas leadership team remains at the helm of the combined
company in Latam. Biopas name will be retained for Latam
operations, even as Biopas becomes part of the Swixx BioPharma
group.
Jean-Michel Lespinasse, CEO of
Swixx BioPharma, warmly welcomed the Biopas team into the Swixx
BioPharma family: "we look forward to working closely with the
brilliant, dedicated professionals that Biopas has attracted across
Latam," commented Lespinasse. "We shall work passionately,
with respect for Biopas' personnel and entrepreneurial culture, to
join the two companies and thereby create something greater than
the sum of the two parts."
"Let me also take this opportunity to salute Biopas' Founders
Pascal and Maria Fernanda Forget,
who I am happy to announce will join us with the respective
positions of Executive Regional General Manager Latam and Executive
Operations Advisor. The Forgets also become our shareholders and
Pascal will take a role on Swixx BioPharma's Board of
Directors."
Benoit Chastaing, Swixx BioPharma's Non-Executive Board
Member and Managing Partner at Merieux Equity Partners (Swixx
Investor) enthused that "this represents a landmark move
for Swixx. In a stroke, we are creating a well-scaled, completely
new breed of partner for global pharma – offering a genuine,
single-stop shop with real presence in three continents. This gives
to multinational biopharma, for the first time, a capable, serious
yet simple (and easily managed) strategic alternative to having
direct presence outside of their top 20 global markets."
Pascal Forget,
CEO and co-founder of Biopas, commented: "We
welcome the opportunity to join the Swixx BioPharma group and
contribute to the development of a broad and distinctive
interregional platform. We strongly believe that by joining forces
with Swixx, we will be better placed to fulfill our mission to
bring innovative medicines to the Latin American population. Both
companies have similar missions and business models, and their
combination will generate significant value for our partners and
our patients. We will continue to provide efficient solutions and
unlock access in the region, while nurturing long-term
relationships with all Biopas stakeholders."
About Swixx BioPharma
Swixx BioPharma operates fully owned subsidiaries across Central
and Eastern Europe, Greece, Russia and several Eurasian countries
including Belarus, Kazakhstan, Uzbekistan, the Middle East and now Latin America. Swixx BioPharma has over 1,300
employees and sales likely to exceed a billion Euros in 2024. The
company is one of the fastest-growing, largest, independent,
intercontinental commercial platforms for the biopharmaceutical
industry. Swixx has gathered outstanding rare disease,
oncology-hematology, specialty, vaccines and self-medication talent
under one roof. For more information about Swixx BioPharma, please
visit: www.swixxbiopharma.com.
About Laboritorios Biopas Group
Biopas is a leading pharmaceutical company in Latin America, specializing in the
in-licensing, marketing, and sale of cutting-edge specialty
pharmaceutical products. Our mission is to address unmet medical
needs and facilitate access to innovative medicines. We provide
efficient solutions to international pharmaceutical companies
seeking to tap into sales opportunities across the region.
Operating throughout Latin America
with fully owned subsidiaries, we hold leading positions in CNS,
Immunology, Dermatology, Gastroenterology, Oncology, and Rare
Disease biopharmaceuticals. Our anticipated sales for 2024 are
approximately $220 million, supported
by a dedicated team of over 300 employees.
Swixx BioPharma Investor and partner inquiries:
Jean-Michel Lespinasse, CEO
bd.info@swixxbiopharma.com
Stuart Swanson, Head of Corporate
Development
bd.info@swixxbiopharma.com
Swixx BioPharma media inquiries:
Vedrana Sokac Brataljenovic, Public Affairs Director
vedrana.sokac@swixxbiopharma.com, Tel: +385 1 425 6086
Biopas inquiries:
Pascal Forget, Executive Regional
General Manager Latam
bd@biopasgroup.com
Photo -
https://mma.prnewswire.com/media/2417969/FT_Statista.jpg
Logo -
https://mma.prnewswire.com/media/2417970/Swixx_BioPharma_Logo.jpg
View original content to download
multimedia:https://www.prnewswire.com/news-releases/swixx-biopharma-expands-to-latin-america-through-a-strategic-acquisition-and-combination-with-biopas-302152037.html
SOURCE Swixx BioPharma